The Relationship between Oxidative Stress and Coronary Artery Calcification in Patients Undergoing Peritoneal Dialysis or Hemodialysis

被引:1
作者
Erdur, Fatih Mehmet [1 ]
Turkmen, Kultigin [2 ]
Kayikcioglu, Hatice [3 ]
Ozcicek, Fatih [4 ]
Toker, Aysun [5 ]
Ozbek, Orhan [6 ]
Turk, Suleyman [1 ]
Tonbul, Halil Zeki [1 ]
机构
[1] Necmettin Erbakan Univ, Meram Sch Med, Dept Nephrol, Meram, Konya, Turkey
[2] Erzincan Univ, Mengucek Gazi Training & Res Hosp, Dept Nephrol, Erzincan, Turkey
[3] Necmettin Erbakan Univ, Meram Sch Med, Dept Internal Med, Meram, Konya, Turkey
[4] Erzincan Univ, Mengucek Gazi Training & Res Hosp, Dept Internal Med, Erzincan, Turkey
[5] Necmettin Erbakan Univ, Meram Sch Med, Dept Biochem, Meram, Konya, Turkey
[6] Necmettin Erbakan Univ, Meram Sch Med, Dept Radiol, Meram, Konya, Turkey
来源
EUROPEAN JOURNAL OF GENERAL MEDICINE | 2015年 / 12卷 / 01期
关键词
Hemodialysis; peritoneal dialysis; oxidative stress; vascular calcification;
D O I
10.15197/sabad.1.12.09
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vascular calcification and increased oxidative stress are commonly seen in patients with end-stage renal disease (ESRD). Nitrotyrosine is one of the end products of nitric oxide metabolism and is accepted as an indicator of oxidative stress. Nitrotyrosine levels have been found to be high in ESRD patients. The aim of our study is to investigate the relation between coronary artery calcification and oxidative stress in peritoneal dialysis (PD) and hemodialysis (HD) patients. 46 PD and 34 HD patients are included in the study. Coronary artery calcification scoring (CACS) is made by multi slice computed tomography. Patients are divided into 4 groups according to their CACS values as Group 1 (CACS: 0), Group 2 (CACS: 1-99), Group 3 (CACS: 100-399) and Group 4 (CACS: >= 400). Serum nitrotyrosine levels were measured. Nitrotyrosine levels were significantly increased in HD patients compared to PD patients. Nitrotyrosine levels were found to be elevated in accordance with increased CACS in PD patients. However, we could not find this relationship in HD patients. There might be an important relationship between CACS and oxidative stress in PD patients.
引用
收藏
页码:53 / 58
页数:6
相关论文
共 17 条
[1]   QUANTIFICATION OF CORONARY-ARTERY CALCIUM USING ULTRAFAST COMPUTED-TOMOGRAPHY [J].
AGATSTON, AS ;
JANOWITZ, WR ;
HILDNER, FJ ;
ZUSMER, NR ;
VIAMONTE, M ;
DETRANO, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (04) :827-832
[2]   CUPROPHANE BUT NOT SYNTHETIC MEMBRANE INDUCES INCREASES IN SERUM TUMOR-NECROSIS-FACTOR-ALPHA LEVELS DURING HEMODIALYSIS [J].
CANIVET, E ;
LAVAUD, S ;
WONG, T ;
GUENOUNOU, M ;
WILLEMIN, JC ;
POTRON, G ;
CHANARD, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (01) :41-46
[3]   Vascular calcifications in uremia: Old concepts and new insights [J].
Derici, U ;
El Nahas, AM .
SEMINARS IN DIALYSIS, 2006, 19 (01) :60-68
[4]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[5]   Increased Calcification and Protein Nitration in Arteries of Chronic Kidney Disease Patients [J].
Guilgen, Gisah ;
Werneck, Marilia Lacerda ;
de Noronha, Lucia ;
Camargo Martins, Ana Paula ;
Varela, Alexandre M. ;
Nakao, Lia Sumie ;
Pecoits-Filho, Roberto .
BLOOD PURIFICATION, 2011, 32 (04) :296-302
[6]  
Kim HI, 2013, IRAN J KIDNEY DIS, V7, P453
[7]   Arterial calcification in patients with chronic kidney disease [J].
Koleganova, Nadezda ;
Piecha, Grzegorz ;
Ritz, Eberhard ;
Schirmacher, Peter ;
Mueller, Annett ;
Meyer, Hans-Peter ;
Gross, Marie-Luise .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (08) :2488-2496
[8]   Nitric oxide insufficiency, platelet activation, and arterial thrombosis [J].
Loscalzo, J .
CIRCULATION RESEARCH, 2001, 88 (08) :756-762
[9]   Increased plasma S-nitrosothiol levels in chronic haemodialysis patients [J].
Massy, ZA ;
Borderie, D ;
Nguyen-Khoa, T ;
Drüeke, TB ;
Ekindjian, OG ;
Lacour, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (01) :153-157
[10]  
Namiduru ES, 2010, MINERVA MED, V101, P305